Analysts count on revenue decrease Gilead Sciences

Tomorrow Gilead Sciences will report her past quarter's results. For this year the consensus of the revenue equals 30,34 billion dollars. This is slightly lower than the 2015's revenue of 32,64 billion dollars.

Historical revenues and results Gilead Sciences plus taxations 2016

fundamental research

The analysts expect for 2016 a net profit of 16,05 billion dollars. For the current year the consensus of the result per share is a profit of 11,75 dollars. Based on this the price/earnings-ratio equals 6,29.

Per share a dividend of 1,85 dollars is expected. Consequently Gilead Sciences 's dividend return equals 2,5 percent. On average the biotech company yields a rather limited dividend yield of around 0,25 percent.

Latest target prices around 102 dollars

The stock Gilead Sciences is being covered by 6 fundamental analysts. The average target price for the stock is at 108,33 dollars. This is around 47 percent more than the current stock price of 73,88 dollars. BMO Capital Markets, Jefferies & Co. and JP Morgan recently provided recommendations for the company.

Based on the number of outstanding shares Gilead Sciences 's market capitalization equals 105,06 billion dollars.

Friday the stock closed at 73,88 dollars. News Wire & Equity Research: +31 084-0032-842

Copyright B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.